Park Avenue Securities’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.57M | Buy |
+7,248
| New | +$1.39M | 0.01% | 774 |
|
|
2026
Q1 | – | Sell |
-3,030
| Closed | -$533K | – | 1533 |
|
|
2025
Q4 | $533K | Sell |
3,030
-417
| -12% | -$68.1K | ﹤0.01% | 1066 |
|
|
2025
Q3 | $483K | Buy |
3,447
+244
| +8% | +$33K | ﹤0.01% | 1200 |
|
|
2025
Q2 | $402K | Buy |
3,203
+137
| +4% | +$17.1K | ﹤0.01% | 1158 |
|
|
2025
Q1 | $420K | Buy |
3,066
+759
| +33% | +$109K | 0.01% | 903 |
|
|
2024
Q4 | $353K | Sell |
2,307
-323
| -12% | -$54.5K | ﹤0.01% | 1214 |
|
|
2024
Q3 | $510K | Buy |
2,630
+101
| +4% | +$21.1K | 0.01% | 956 |
|
|
2024
Q2 | $586K | Buy |
2,529
+193
| +8% | +$41.9K | 0.01% | 896 |
|
|
2024
Q1 | $504K | Sell |
2,336
-215
| -8% | -$50.4K | 0.01% | 943 |
|
|
2023
Q4 | $660K | Sell |
2,551
-281
| -10% | -$69K | 0.01% | 793 |
|
|
2023
Q3 | $728K | Buy |
+2,832
| New | +$757K | 0.01% | 691 |
|
|
2023
Q1 | – | Sell |
-1,698
| Closed | -$470K | – | 748 |
|
|
2022
Q4 | $470K | Buy |
1,698
+226
| +15% | +$63.8K | 0.01% | 797 |
|
|
2022
Q3 | $393K | Buy |
1,472
+166
| +13% | +$35.3K | 0.01% | 806 |
|
|
2022
Q2 | $266K | Buy |
1,306
+247
| +23% | +$50.5K | 0.01% | 966 |
|
|
2022
Q1 | $223K | Buy |
1,059
+209
| +25% | +$45.4K | ﹤0.01% | 1053 |
|
|
2021
Q4 | $204K | Sell |
850
-436
| -34% | -$112K | ﹤0.01% | 1057 |
|
|
2021
Q3 | $364K | Buy |
1,286
+55
| +4% | +$18K | 0.01% | 781 |
|
|
2021
Q2 | $426K | Sell |
1,231
-267
| -18% | -$80.9K | 0.01% | 696 |
|
|
2021
Q1 | $419K | Buy |
1,498
+280
| +23% | +$75.5K | 0.01% | 640 |
|
|
2020
Q4 | $298K | Sell |
1,218
-746
| -38% | -$192K | 0.01% | 688 |
|
|
2020
Q3 | $557K | Buy |
1,964
+85
| +5% | +$23.7K | 0.02% | 407 |
|
|
2020
Q2 | $503K | Buy |
1,879
+323
| +21% | +$97.1K | 0.02% | 393 |
|
|
2020
Q1 | $492K | Buy |
1,556
+515
| +49% | +$156K | 0.04% | 152 |
|
|
2019
Q4 | $309K | Buy |
1,041
+99
| +11% | +$27.5K | 0.01% | 457 |
|
|
2019
Q3 | $219K | Buy |
942
+39
| +4% | +$9.08K | 0.01% | 474 |
|
|
2019
Q2 | $211K | Sell |
903
-79
| -8% | -$18.2K | 0.02% | 247 |
|
|
2019
Q1 | $228K | Sell |
982
-32
| -3% | -$10.1K | 0.01% | 410 |
|
|
2018
Q4 | $338K | Buy |
1,014
+388
| +62% | +$124K | 0.05% | 106 |
|
|
2018
Q3 | $221K | Buy |
+626
| New | +$216K | 0.04% | 176 |
|
Other funds holding BIIB
Park Avenue Securities's BIIB Position: Q2 2026 in Review
Park Avenue Securities opened a new position in Biogen (BIIB) in Q2 2026: 7,248 shares worth $1.57M. The stake represents 0.01% of the portfolio and ranks #774 among its holdings. This is a return to the name: Park Avenue Securities previously reported a position in BIIB as recently as Q4 2025.
Park Avenue Securities first reported a position in BIIB in Q3 2018 and has held it in 29 quarters since. 1,044 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Park Avenue Securities held 7,248 shares of Biogen worth $1.57M as of Q2 2026.
- Biogen was a new Park Avenue Securities position in Q2 2026.
- Biogen made up 0.01% of Park Avenue Securities's portfolio in Q2 2026, its #774 holding.
- Park Avenue Securities first reported a position in Biogen in Q3 2018 and has held it in 29 quarters since.
- 1,044 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.